ImmunoPrecise antibodies is a company that specialized in the production of custom antibodies, the Y-shaped molecules produced by living things to defend itself from infection. Their ability to recognize and bind to specific targets allows for their use in diverse scientific analyses where their specificity of binding is manipulated to allow for localization and/or isolation of specific targets.
Global population growth, urbanization and changing climate patterns have increased the demand for potable water, wastewater reuse and value recovery from wastewater, and for remediation of industrial process water. Population growth also results in increased demand for the shipping of goods by ocean freight, with the associated risk of the transport of unwanted marine life from one location to another by the discharge of ballast water.
Antibiotic resistance represents a major health problem for society. With the expanded use of antibiotics, microorganisms have developed various mechanisms of resistance to overcome the effects of once highly effective agents. There is therefore an urgent need to identify new therapies to counteract resistant strains. The intern will design and identify new drugs that are capable of treating patients infected with bacterial strains showing resistance to current drugs used in the clinic.
To ensure effective cancer treatment, it is vital to match the drug with the molecular characteristics of the patients tumor. This research project is focused on developing functional diagnostic assays that may be used eventually in the clinic to stratify patients for targeted therapies. The project will provide a unique opportunity for the interns to work with a clinician at the forefront of cancer treatment and scientists of a partner organization that is developing innovative tools to enable precision cancer medicine.
Many human genetic diseases are associated with defects in post-transcriptional gene regulation and alternative splicing. Despite rapid technological advancements, successful diagnostic rates for rare genetic disorders are still low and clinical interventions and treatments unavailable for most patients. This project aims to address this challenge by developing novel antisense RNA therapies based on the splice-switching oligonucleotide (SSO) technology. SSOs allow correcting aberrant transcript splicing by targeting disease mutations at the transcript level.
The current production methods for new generation refrigerants (HFO-1234yf) used in cars, refrigerators, air-conditioners, etc. require energy intensive and sometimes corrosive conditions. The current project seeks to reduce or eliminate these two caveats. We propose, by using readily available feedstock or by-products from Teflon manufacturing, we could use our process to easily manufacture HFO-1234yf. Using our less energy intensive, heating to only 50 °C, and mild conditions could lead to significant cost reductions in plant equipment and energy demands.
Glioblastoma (GBM) is the most common primary adult brain tumor. Even with surgery, standard chemotherapy, and radiation, tumor recurrence and patient relapse are inevitable with a median survival rate of
Neisseria meningitidis (Nme) is a bacterial pathogen that often colonizes the upper respiratory tract of humans without symptoms, but which may also develop into rapidly-progressing sepsis and meningitis that can be fatal. Nme has evolved elegant means to specifically interact with human cells and proteins in order to colonize, survive and evade the host immune system. In partnership with Vaxiron Inc., we are developing a novel class of vaccines that target systems involved in Nme acquisition of the essential micronutrient, iron, during infection.
Significant advances in technologies related to antibody discovery and development have allowed therapeutic antibodies to become the fastest growing class of biopharmaceuticals over the last 20 years. Northern Biologics is a biotechnology company that seeks to develop therapeutic antibodies for the treatment of cancer and fibrosis. Together with Dr. Jean-Philippe Julien at SickKids (University of Toronto), the intern will work with Northern Biologics to develop and characterize antibodies against cellular receptors that show aberrant signaling in several diseases including cancer.
Pig production is a vital component of the Canadian agricultural sector. Airborne bacterial pathogens Haemophilus parasuis, Actinobacillus pleuropneumoniae and Actinobacillus suis are major causes of swine respiratory disease and cause rapidly progressing systemic infections that lead to significant morbidity and mortality. We are developing engineered subunit vaccines that can simultaneously target all three pathogens and can be formulated for needle-free delivery using pressure guns.